CTI Biopharma | CTIC

CTI Biopharma traded at $4.51 this Wednesday March 29th, increasing $0.14 or 3.15 percent since the previous trading session. Looking back, over the last four weeks, CTI Biopharma gained 17.14 percent. Over the last 12 months, its price fell by 10.03 percent. Looking ahead, we forecast CTI Biopharma to be priced at 4.16 by the end of this quarter and at 3.78 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
4.48
Daily Change
2.46%
Yearly
-10.63%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Baxter International 40.20 0.35 0.88% -49.36%
Bristol-Myers Squibb 67.98 -0.22 -0.32% -7.79%
CTI Biopharma 4.48 0.11 2.46% -10.63%
Plus Therapeutics, Inc. 0.27 -0.002 -0.81% -72.97%
Geron 2.22 0.05 2.07% 38.44%
Incyte Corp 70.60 0.29 0.41% -11.38%
Eli Lilly 335.87 -1.78 -0.53% 15.86%
Mirati Therapeutics 38.30 1.76 4.82% -53.97%
Novartis 82.93 -0.54 -0.65% 1.57%
Novartis 90.02 -0.93 -1.02% 2.34%
Northwest Biotherapeutics 0.61 -0.02 -2.56% -12.37%
Seattle Genetics 203.13 0.11 0.05% 43.49%
Teva Pharmaceutical Industries 8.80 0.04 0.46% -6.18%

Indexes Price Day Year
USND 11889 173.19 1.48% -17.68%
US2000 1764 11.66 0.67% -15.63%

CTI Biopharma
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.